A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

This study was for adults aged 18 or older, of any gender. To be considered, you would have needed to have invasive HER2-positive breast cancer that was confirmed by lab tests. An important requirement was that you had already completed chemotherapy treatment before your breast cancer surgery, and this treatment must have included certain drugs like taxane and trastuzumab. Crucially, after your surgery, there must have still been some cancer cells found in your breast or nearby lymph nodes.

You also needed to be in reasonably good general health, with a good ability to perform daily activities. Your heart function, which would have been checked with a test called an LVEF, needed to be at a certain level. People with very early-stage cancers (like some T1 cancers) or those with cancer that had spread to other parts of the body (Stage IV) were not eligible. Also, if you had certain other health conditions, such as severe nerve damage, specific lung problems, autoimmune diseases, or other serious illnesses, you couldn't join. You also couldn't have previously received certain similar cancer drugs.

As this study is now closed to new participants, we can't describe what taking part would involve in real-time. However, typically, a study like this would involve regular hospital visits for check-ups, blood tests, and to receive the study medications. You would have had follow-up appointments over several years to monitor your health and see if the cancer returned. The total duration of active treatment and follow-up can vary greatly in clinical trials, but typically involves a commitment over a number of years.